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Background and Significance
❑Chemotherapy may lead to breakdown of nonkeratinized oral 
tissues causing:
❑ Negative nutritional impact
❑ Poorer quality of life
❑ Pain
❑ Dehydration
❑ Life-threatening infections
❑ Linked to poorer patient outcomes impacting mortality
❑Oral mucositis is a common complication of chemotherapy 
treatment
(Eilers et al., 2014; Campos et al., 2014; Carvalho, Medeiros-Filho, & Ferreira, 2018; Slade, 2017; Yarom
et. al, 2013Panahi et al., 2016, Lee, 2013 & Cullen et al., 2018).
PICOT
❑ In patients receiving oncological treatments, does an oral care protocol with 
zinc sulfate supplementation, compared to the standard of care (oral 
protocol alone), reduce complications related to oral mucositis as measured 
by a patient-reported assessment tool over a six-week period?
Decision to Change Practice
Establish and implement an oral care protocol
❑ Participant take-home materials
❑ Staff education 
Incorporate use of subjective tool to capture the patient experience of oral 
mucositis 
❑ Less painful than observational assessment
❑ Reinforces the importance of oral care to prevent symptoms
Incorporate zinc supplementation as a preventive measure for 
experimental group and compare to group that is receiving oral care 
protocol alone
❑ Participants to complete subjective survey 
❑Monitor for six weeks across patients receiving a wide variety of 
chemotherapies for different types of cancers
Review of Literature
❑ Keywords: “oral mucositis” and prevent* were used across all databases. 
“cancer” OR “chemo*” and “adult” in select data bases
❑ Inclusion: English, scholarly or academic, peer reviewed, 2013 and 2018, 
and goal to prevent OM.
❑ Exclusion: pediatric populations, limited to one specific chemotherapy 
agent, use of drugs not approved in the US, failure to include 
recommendations, and timeliness of data at time of publication
Implementation
Setting: Outpatient oncology office 
Design: Two-group pretest-posttest quasi-experimental design
Program Interventions: Creation of an oral care protocol, extensive staff 
education, collection of data using the PROMS survey (a 100-mm visual analog 
scale) (Kushner et al., 2008)
Theoretical Framework: Self-Care Theory (Orem, 2001)
Evidence-Based Practice Model:  Johns Hopkins Nursing Evidenced-Based 
Practice Model (JHNEBP Model) (Dang & Dearholt, 2017)
Timeframe: Rolling entry dates with data collected weekly over six-weeks
Conclusions
A multi-faceted intervention including the development of an oral care 
protocol, staff education, use of subjective oral mucositis tool, and zinc 
supplementation may: 
❑ Increase knowledge of oral care during chemotherapy for both clinical 
personnel and the patients that they treat
❑ Use of a subjective patient survey is valuable in outpatient 
chemotherapy infusion centers 
❑ Zinc supplementation may shorten duration and intensity of symptoms in 
8 out of 10 subjective areas on the PROMS scale
Recommendations
❑ Development and standardization of an oral care protocol is 
recommended for all outpatient settings that administer chemotherapy 
❑More sophisticated investigation is needed to explore if zinc 
supplementation is appropriate to prescribe to all patients receiving 
chemotherapy
❑ Future EBP project should preform analysis on a larger population of 
patients receiving chemotherapy in order to confirm the ability to 
generalize findings
❑ Future EBP projects should ensure consistency of zinc supplements to 
reduce possible inconsistencies 
❑ Future EBP projects should provide supplies needed to complete oral 
care as recommended in their oral care protocol.  
Appraisal
Database Yielded Reviewed Accepted
CINAHL 35 8 4
Medline 270 12 5
Cochrane 5 2 0
JBI 35 6 2
Nursing & Allied Health 
Database
18 3 0
National Guidelines 
Clearinghouse
16 1 0
Hand Searched 5 5 2
Total 384 37 13
Evaluation
Primary Outcomes: Statistically significant differences were found in 8 out 
of 10 oral mucositis symptoms addressed on PROMS survey.
Participants in Non-Zinc Group (n=11)Participants in Zinc Group (n=12)
AFRICAN
AMERICAN
HISPANIC
WHITE
ASAIN
Zinc group (%)  (n=12) Non-Zinc Group (%)  (n=11)
Male 5 (41.7) 9 (81.8)
Female 7 (58.3) 2 (18.2)
Age Range
41-55 1 (8.3) 2 (18.2)
56-65 5 (41.7) 5 (35.5)
66-75 3 (25.0) 2 (18.2)
76-85 2 (16.7) 2 (18.2)
86-90 1 (8.3) 0
Cancer Types
Lung cancer 6 (50.0) 5 (45.5)
Breast cancer 2 (16.7) 1 (9.1)
Colorectal cancer 1 (8.3) 2 (18.2)
Non-Hodgkin’s lymphoma 1 (8.3) 0
Leukemia 1 (8.3) 0
Pancreatic cancer 0 2 (18.2)
Other endocrine cancer 1 (8.3) 0
Laryngeal cancer 0 1 (9.1)
Metastases
No Metastases 7 (58.3) 3 (27.3)
Metastases 5 (41.7) 8 (72.7)
❑ Appraisal of Evidence: The Johns Hopkins Tools
❑Quality: Johns Hopkins Nursing Evidenced-Based Practice Model 
(JHNEBP Model) Research and Non-Research Evidence Appraisal  (Dang & 
Dearholt, 2017).
Patient Characteristics
PROMS survey 
Assessment
Week 3
Zinc vs. Non-
Zinc
(p=)
Week 4
Zinc vs. Non-
Zinc
(p=)
Week 5
Zinc vs. Non-
Zinc
(p=)
Week 6
Zinc vs. Non-
Zinc
(p=)
Mouth Pain 2.91 vs. 8.75
(p = .046)
2 vs. 8.91
(p = .004)
Difficulty Swallowing 2.7 vs. 7.33
(p = .008)
1.18 vs. 3.36
(p = .036)
Difficulty Eating Soft 
Foods
2 vs. 4.2
(p = .024) 
1.82 vs. 7.25
(p = .008)
Restriction of Eating 3.45 vs. 11.82
( p = .017)
Difficulty Drinking 2 vs. 5
(p = .024)
1.36 vs. 3.7
(p = .023)
Restriction of 
Drinking
1.2 vs. 2.7,
(p = .033)
Difficulty Swallowing 2 vs. 6.89
(p = .048) 
1.91 vs. 8.25
(p = .027)
Change in Taste 6.3 vs. 14.33
(p = .045) 
4.55 vs. 16.88
(p = .04)
Restriction of speech 
Difficulty eating hard 
foods
There were no statistically significant differences in the groups with 
regards to restriction of speech or difficulty eating hard foods.  
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